{
  "extraction_metadata": {
    "timestamp": "2025-09-10T07:55:04.877956",
    "source_type": "hta_submission",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "total_countries": 8,
    "total_picos": 26
  },
  "picos_by_country": {
    "DK": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DK",
      "PICOs": [
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel monotherapy",
          "Outcomes": "investigator-assessed progression-free survival (PFS), overall survival (OS), event-free survival, time to progression (TTP), time to next treatment (TTNT), objective response rate (ORR), disease control rate, response rates, time to response, duration of response, adverse events (AEs), treatment discontinuations due to AEs, grade 3 or higher adverse events, health-related quality of life (HRQoL), quality of life measured by EORTC QLQ-C30, EQ-5D-5L health state utility values"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "standard of care therapy",
          "Outcomes": "investigator-assessed progression-free survival (PFS), overall survival (OS), event-free survival, time to progression (TTP), time to next treatment (TTNT), objective response rate (ORR), disease control rate, response rates, time to response, duration of response, adverse events (AEs), treatment discontinuations due to AEs, grade 3 or higher adverse events, health-related quality of life (HRQoL), quality of life measured by EORTC QLQ-C30, EQ-5D-5L health state utility values"
        }
      ],
      "ChunksUsed": 44,
      "ContextTokens": 11698
    },
    "IT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "IT",
      "PICOs": [
        {
          "Population": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "standard of care therapy",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 12,
      "ContextTokens": 3288
    },
    "DE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DE",
      "PICOs": [
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Docetaxel",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded, independent central review), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (EQ-5D VAS), health-related quality of life (no assessable data), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, specific adverse events (interstitial lung disease [severe AE], liver disorders [severe AEs], stomatitis [AE], peripheral oedema [AE], peripheral neuropathy [AE], alopecia [AE], blood and lymphatic system disorders [AE], fatigue [AE], fever [AE], infections and infestations [AE])"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Pemetrexed",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded, independent central review), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (EQ-5D VAS), health-related quality of life (no assessable data), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, specific adverse events (interstitial lung disease [severe AE], liver disorders [severe AEs], stomatitis [AE], peripheral oedema [AE], peripheral neuropathy [AE], alopecia [AE], blood and lymphatic system disorders [AE], fatigue [AE], fever [AE], infections and infestations [AE])"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Nivolumab",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded, independent central review), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (EQ-5D VAS), health-related quality of life (no assessable data), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, specific adverse events (interstitial lung disease [severe AE], liver disorders [severe AEs], stomatitis [AE], peripheral oedema [AE], peripheral neuropathy [AE], alopecia [AE], blood and lymphatic system disorders [AE], fatigue [AE], fever [AE], infections and infestations [AE])"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Pembrolizumab",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded, independent central review), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (EQ-5D VAS), health-related quality of life (no assessable data), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, specific adverse events (interstitial lung disease [severe AE], liver disorders [severe AEs], stomatitis [AE], peripheral oedema [AE], peripheral neuropathy [AE], alopecia [AE], blood and lymphatic system disorders [AE], fatigue [AE], fever [AE], infections and infestations [AE])"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Atezolizumab",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded, independent central review), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (EQ-5D VAS), health-related quality of life (no assessable data), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, specific adverse events (interstitial lung disease [severe AE], liver disorders [severe AEs], stomatitis [AE], peripheral oedema [AE], peripheral neuropathy [AE], alopecia [AE], blood and lymphatic system disorders [AE], fatigue [AE], fever [AE], infections and infestations [AE])"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Docetaxel in combination with nintedanib",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded, independent central review), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (EQ-5D VAS), health-related quality of life (no assessable data), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, specific adverse events (interstitial lung disease [severe AE], liver disorders [severe AEs], stomatitis [AE], peripheral oedema [AE], peripheral neuropathy [AE], alopecia [AE], blood and lymphatic system disorders [AE], fatigue [AE], fever [AE], infections and infestations [AE])"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy and PD-L1 negative tumours",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Docetaxel",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded, independent central review), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (EQ-5D VAS), health-related quality of life (no assessable data), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, specific adverse events (interstitial lung disease [severe AE], liver disorders [severe AEs], stomatitis [AE], peripheral oedema [AE], peripheral neuropathy [AE], alopecia [AE], blood and lymphatic system disorders [AE], fatigue [AE], fever [AE], infections and infestations [AE])"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy and PD-L1 negative tumours",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Pemetrexed",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded, independent central review), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (EQ-5D VAS), health-related quality of life (no assessable data), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, specific adverse events (interstitial lung disease [severe AE], liver disorders [severe AEs], stomatitis [AE], peripheral oedema [AE], peripheral neuropathy [AE], alopecia [AE], blood and lymphatic system disorders [AE], fatigue [AE], fever [AE], infections and infestations [AE])"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy and PD-L1 negative tumours and adenocarcinoma histology",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Docetaxel in combination with nintedanib",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded, independent central review), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (EQ-5D VAS), health-related quality of life (no assessable data), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, specific adverse events (interstitial lung disease [severe AE], liver disorders [severe AEs], stomatitis [AE], peripheral oedema [AE], peripheral neuropathy [AE], alopecia [AE], blood and lymphatic system disorders [AE], fatigue [AE], fever [AE], infections and infestations [AE])"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy and PD-L1 expressing tumours (PD-L1 expression ≥ 1% of tumour cells)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Pembrolizumab",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded, independent central review), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (EQ-5D VAS), health-related quality of life (no assessable data), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, specific adverse events (interstitial lung disease [severe AE], liver disorders [severe AEs], stomatitis [AE], peripheral oedema [AE], peripheral neuropathy [AE], alopecia [AE], blood and lymphatic system disorders [AE], fatigue [AE], fever [AE], infections and infestations [AE])"
        }
      ],
      "ChunksUsed": 44,
      "ContextTokens": 10591
    },
    "PO": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "PO",
      "PICOs": [
        {
          "Population": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "",
          "Outcomes": "progression-free survival (PFS; median values reported: 5.6 months [95% CI 4.3; 7.8] in CodeBreaK 200, 6.1 months [95% CI: 5.6; not reached] in Julve 2021, 6.7 months [95% CI: 4.6; 8.3] in Awad 2022, with ECOG 0: 6.4 months [95% CI: 2.7; 12.8], ECOG 1: 7.1 months [95% CI: 3.6; 9.0], ECOG 2: 6.5 months), overall response rate (ORR; SOT 28% vs DOC 13%, RR [95% CI] = 2.12 [1.35; 3.33]), disease control rate (DCR; SOT 83% vs DOC group), overall survival (OS; median 12.5 months [95% CI: 10.0; not achieved] in CodeBreaK 100, no statistically significant differences between therapies), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires; no statistically significant differences between groups for endpoints in these questionnaires), adverse events (AEs; including ≥3 severity, treatment-related AEs leading to discontinuation, serious adverse events [SAEs], specific adverse events occurring in ≥10% of patients: diarrhoea, increased ALT, increased AST, fatigue, fever, peripheral oedema, constipation, anaemia, increased asparagine aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, treatment-related AEs ≥ grade 3 in 23% of patients, treatment-related AEs leading to discontinuation in 7%, dose modification-related ADRs in 26%, treatment-associated AEs resulting in death in 1%), economic outcomes (incremental cost-effectiveness ratio [ICUR] from the NFZ perspective, cost-utility analysis [CUA], budgetary impact analysis, estimated monthly costs of treatment), time to progression on subsequent therapy, time to deterioration in quality of life (as measured by EORTC QLQ-C30 and QLQ-LC13), frequency of observation of symptoms and problems associated with lung cancer (as measured by EORTC QLQ-LC13: pain, swelling of the lung, difficulty breathing, loss of hair, bleeding in the chest, cough)"
        }
      ],
      "ChunksUsed": 44,
      "ContextTokens": 10268
    },
    "PT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "PT",
      "PICOs": [
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "overall survival (OS; including median OS, hazard ratio for OS, and 12-month OS rate), progression-free survival (PFS; including median PFS, hazard ratio for PFS, and 12-month PFS rate), objective response rate (ORR; defined as per RECIST v1.1), duration of response (DoR), disease control rate, time to progression, time to next treatment, event-free survival, quality of life (overall health status and physical functioning, including change from baseline to week 12 and time to deterioration), adverse event rate (AEs; assessed by CTCAE v5), rate of grade 3-4 adverse events, discontinuation rate due to adverse events, mortality-related toxicity, dropout rate, morbidity and mortality associated with clinical events"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel + nintedanib",
          "Outcomes": "overall survival (OS; including median OS, hazard ratio for OS, and 12-month OS rate), progression-free survival (PFS; including median PFS, hazard ratio for PFS, and 12-month PFS rate), objective response rate (ORR; defined as per RECIST v1.1), duration of response (DoR), disease control rate, time to progression, time to next treatment, event-free survival, quality of life (overall health status and physical functioning, including change from baseline to week 12 and time to deterioration), adverse event rate (AEs; assessed by CTCAE v5), rate of grade 3-4 adverse events, discontinuation rate due to adverse events, mortality-related toxicity, dropout rate, morbidity and mortality associated with clinical events"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pemetrexed",
          "Outcomes": "overall survival (OS; including median OS, hazard ratio for OS, and 12-month OS rate), progression-free survival (PFS; including median PFS, hazard ratio for PFS, and 12-month PFS rate), objective response rate (ORR; defined as per RECIST v1.1), duration of response (DoR), disease control rate, time to progression, time to next treatment, event-free survival, quality of life (overall health status and physical functioning, including change from baseline to week 12 and time to deterioration), adverse event rate (AEs; assessed by CTCAE v5), rate of grade 3-4 adverse events, discontinuation rate due to adverse events, mortality-related toxicity, dropout rate, morbidity and mortality associated with clinical events"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "nivolumab",
          "Outcomes": "overall survival (OS; including median OS, hazard ratio for OS, and 12-month OS rate), progression-free survival (PFS; including median PFS, hazard ratio for PFS, and 12-month PFS rate), objective response rate (ORR; defined as per RECIST v1.1), duration of response (DoR), disease control rate, time to progression, time to next treatment, event-free survival, quality of life (overall health status and physical functioning, including change from baseline to week 12 and time to deterioration), adverse event rate (AEs; assessed by CTCAE v5), rate of grade 3-4 adverse events, discontinuation rate due to adverse events, mortality-related toxicity, dropout rate, morbidity and mortality associated with clinical events"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab",
          "Outcomes": "overall survival (OS; including median OS, hazard ratio for OS, and 12-month OS rate), progression-free survival (PFS; including median PFS, hazard ratio for PFS, and 12-month PFS rate), objective response rate (ORR; defined as per RECIST v1.1), duration of response (DoR), disease control rate, time to progression, time to next treatment, event-free survival, quality of life (overall health status and physical functioning, including change from baseline to week 12 and time to deterioration), adverse event rate (AEs; assessed by CTCAE v5), rate of grade 3-4 adverse events, discontinuation rate due to adverse events, mortality-related toxicity, dropout rate, morbidity and mortality associated with clinical events"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "platinum doublet",
          "Outcomes": "overall survival (OS; including median OS, hazard ratio for OS, and 12-month OS rate), progression-free survival (PFS; including median PFS, hazard ratio for PFS, and 12-month PFS rate), objective response rate (ORR; defined as per RECIST v1.1), duration of response (DoR), disease control rate, time to progression, time to next treatment, event-free survival, quality of life (overall health status and physical functioning, including change from baseline to week 12 and time to deterioration), adverse event rate (AEs; assessed by CTCAE v5), rate of grade 3-4 adverse events, discontinuation rate due to adverse events, mortality-related toxicity, dropout rate, morbidity and mortality associated with clinical events"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy and tumours expressing PD-L1 with a TPS >=1%",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pembrolizumab",
          "Outcomes": "overall survival (OS; including median OS, hazard ratio for OS, and 12-month OS rate), progression-free survival (PFS; including median PFS, hazard ratio for PFS, and 12-month PFS rate), objective response rate (ORR; defined as per RECIST v1.1), duration of response (DoR), disease control rate, time to progression, time to next treatment, event-free survival, quality of life (overall health status and physical functioning, including change from baseline to week 12 and time to deterioration), adverse event rate (AEs; assessed by CTCAE v5), rate of grade 3-4 adverse events, discontinuation rate due to adverse events, mortality-related toxicity, dropout rate, morbidity and mortality associated with clinical events"
        }
      ],
      "ChunksUsed": 44,
      "ContextTokens": 10908
    },
    "SE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "SE",
      "PICOs": [
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation, in case of progression after at least one previous line of systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel monotherapy",
          "Outcomes": "progression-free survival (PFS), overall survival (OS), health-related quality of life (measured by time to death), quality-adjusted life years (QALYs), safety (as evaluated in CodeBreaK 200), cost per QALY gained"
        },
        {
          "Population": "patients with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation that has progressed after at least one prior systemic therapy and who have been treated with docetaxel or who are not medically suitable for treatment with Docetaxel",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "best supportive care",
          "Outcomes": "progression-free survival (PFS), overall survival (OS), health-related quality of life (measured by time to death), quality-adjusted life years (QALYs), safety (as evaluated in CodeBreaK 200), cost per QALY gained"
        }
      ],
      "ChunksUsed": 44,
      "ContextTokens": 9206
    },
    "EN": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "EN",
      "PICOs": [
        {
          "Population": "KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "overall survival (OS), progression-free survival (PFS), objective response rate (ORR; 37.1% per RECIST 1.1 in CodeBreaK100), health-related quality of life (utilities derived from visual analogue scale in progression-free health state; utility values reported: 0.734 in CodeBreaK100, 0.451 for oral therapy and 0.426 for intravenous therapy in Lewis et al. 2010, and 0.687 from LUME-Lung 1; utility decrement of 0.025 per cycle for cytotoxicity and intravenous administration), safety (adverse events, tolerability), treatment discontinuation (81.7% discontinued at March 2021 data-cut), economic outcomes (cost-effectiveness, health-state utility approach, progression-free survival on-treatment utility differential scenarios of 0.025 or 0.04), end-of-life criteria (life extension for patients with short life expectancy)"
        },
        {
          "Population": "KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel plus nintedanib",
          "Outcomes": "overall survival (OS), progression-free survival (PFS), objective response rate (ORR; 37.1% per RECIST 1.1 in CodeBreaK100), health-related quality of life (utilities derived from visual analogue scale in progression-free health state; utility values reported: 0.734 in CodeBreaK100, 0.451 for oral therapy and 0.426 for intravenous therapy in Lewis et al. 2010, and 0.687 from LUME-Lung 1; utility decrement of 0.025 per cycle for cytotoxicity and intravenous administration), safety (adverse events, tolerability), treatment discontinuation (81.7% discontinued at March 2021 data-cut), economic outcomes (cost-effectiveness, health-state utility approach, progression-free survival on-treatment utility differential scenarios of 0.025 or 0.04), end-of-life criteria (life extension for patients with short life expectancy)"
        }
      ],
      "ChunksUsed": 44,
      "ContextTokens": 9173
    },
    "FR": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "FR",
      "PICOs": [
        {
          "Population": "adult patients with advanced non-small cell bronchial cancer (NSCBC) with the KRAS G12C mutation whose disease has progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "progression-free survival as assessed by an independent, blinded review panel (time between randomization and progression per RECIST 1.1 or death from any cause, with sensitivity analysis considering initiation of new anti-cancer therapy as an event), objective response rate as evaluated by the independent review committee (proportion of patients with complete or partial response per RECIST 1.1), overall survival (time between randomization and death from any cause), duration of response (time from first partial or complete response to first relapse or progression per RECIST 1.1 or death from any cause), disease control rate (proportion of patients with complete, partial, or stable disease response for at least 5 weeks), time to response (time from treatment initiation to first complete or partial response), serious adverse events (incidence reported as over 51% of patients), incidence of serious undesirable effects (≥65% of patients), quality of life (measured by QLQ-C30 and QLQ-LC13 questionnaires, but no formal conclusions due to study limitations)"
        }
      ],
      "ChunksUsed": 44,
      "ContextTokens": 9776
    }
  }
}